Table 2.
Univariable regression of ALCmax with other variables for all patients receiving BCMA CAR-T
| Variable | OR | 95 % CI | P value |
|---|---|---|---|
| Age at CAR-T infusion | 1.03 | 0.98-1.07 | .26 |
| Presence of CRS | |||
| No | — | — | .013 |
| Yes | 5.16 | 1.4-18.7 | |
| Highest CRS grade | |||
| Grade 1 | — | — | .016 |
| Grade 2 | 3.4 | 0.98-11.8 | |
| Grade 3 | 11.7 | 1.5-90.6 | |
| Presence of ICANS∗ | |||
| No | — | — | .004 |
| Yes | 6.7 | 1.8-24.8 | |
| High-risk CG∗ | |||
| No high-risk CG | — | — | .52 |
| High-risk present | 1.3 | 0.5-3.4 | |
| Number of previous lines | 0.9 | 0.8-1.05 | .2 |
| EMD | |||
| Nonparaskeletal EMD absent | — | — | .8 |
| Nonparaskeletal EMD | 1.1 | 0.4-3.2 | |
| ISS stage | |||
| Stage I | — | — | .2 |
| Stage II | 0.4 | 0.1-1.4 | |
| Stage III | 1.2 | 0.3-4.8 | |
| BCMA CAR-T product | |||
| Ide-cel | — | — | <.001 |
| Cilta-cel | 11.5 | 5.16-25.7 | |
The bold character to emphasize on the significant values associated ALC max and for visualization purposes.
∗
Presence of any of deletion 17p/t(4;14)/t(14;16)/gain 1q.